ECONOMIC AND HUMANISTIC BURDEN OF CHRONIC SPONTANEOUS URTICARIA IN BRAZIL- IMPACT ON WORK PRODUCTIVITY, RESOURCE UTILIZATION AND QUALITY OF LIFE

Author(s)

Balp M¹, Lopes N², Tian H³, Vietri J⁴, Ensina LF⁵
¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Brazil, Sao Paulo, Brazil, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ⁴Kantar Health, Horsham, PA, USA, ⁵Federal University of São Paulo, São Paulo, SP, Brazil

Presentation Documents

PHS76--strong-u-balp-m-u-sup-1-sup-strong-lopes-n-sup-2-sup-tian-h-sup-3-sup-vietri-j-sup-4-sup-ensina-lf-sup-5-sup-br-sup-1-sup-novartis-pharma-ag-basel-switzerland-sup-2-sup-novartis-brazil-sao-paulo-brazil-sup-3-sup-novartis-pharmaceutic ...

OBJECTIVES: Data on economic and humanistic burden associated with chronic urticaria (CU) or chronic spontaneous urticaria (CSU) in Brazil are scarce. The current study assesses the economic and humanistic burden of CSU among Brazilian adult patients currently treated for chronic urticaria as a proxy for CSU. METHODS:

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHS76

Topic

Economic Evaluation, Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Presentation